Osteopontin splice variants are differential predictors of breast cancer treatment responsesReport as inadecuate




Osteopontin splice variants are differential predictors of breast cancer treatment responses - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 16:441

Translational oncology

Abstract

BackgroundOsteopontin is a marker for breast cancer progression, which in previous studies has also been associated with resistance to certain anti-cancer therapies. It is not known which splice variants may mediate treatment resistance.

MethodsHere we analyze the association of osteopontin variant expression before treatment, differentiated according to immunohistochemistry with antibodies to exon 4 and to the osteopontin-c splice junction respectively, with the ensuing therapy responses in 119 Polish breast cancer patients who presented between 1995 and 2008.

ResultsWe found from Cox hazard models, logrank test and Wilcoxon test that osteopontin exon 4 was associated with a favorable response to tamoxifen, but a poor response to chemotherapy with CMF cyclophosphamide, methotrexate, fluorouracil. Osteopontin-c is prognostic, but falls short of being a significant predictor for sensitivity to treatment.

ConclusionsThe addition of osteopontin splice variant immunohistochemistry to standard pathology work-ups has the potential to aid decision making in breast cancer treatment.

KeywordsTumor progression marker Immunohistochemistry Breast cancer Chemotherapy Hormone therapy Radiation therapy 



Author: Krzysztof Zduniak - Anil Agrawal - Siddarth Agrawal - Md Monir Hossain - Piotr Ziolkowski - Georg F. Weber

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents